{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:53:52Z","timestamp":1794048832512,"version":"4.8.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jgar.2022.05.009","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:38:36Z","timestamp":1653525516000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6786-2471","authenticated-orcid":false,"given":"Lu-Yan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can-Can","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cui-Zhu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.05.009_bib0001","first-page":"1","article-title":"Deaths: leading causes for 2017","volume":"68","author":"Heron","year":"2019","journal-title":"Natl Vital Stat Rep"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2022.05.009_bib0002","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"key":"10.1016\/j.jgar.2022.05.009_bib0003","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0004","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.009_bib0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2334-14-13","article-title":"A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance","volume":"14","author":"Bell","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.009_bib0006","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1183\/09031936.00154209","article-title":"The impact of a delay in intensive care unit admission for community-acquired pneumonia","volume":"36","author":"Phua","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2022.05.009_bib0007","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/crj.12379","article-title":"Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance","volume":"11","author":"Cao","year":"2017","journal-title":"Clin Respir J"},{"key":"10.1016\/j.jgar.2022.05.009_bib0008","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1164\/rccm.200603-350OC","article-title":"A worldwide perspective of atypical pathogens in community-acquired pneumonia","volume":"175","author":"Arnold","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0009","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1055\/s-0036-1592121","article-title":"Role of atypical pathogens in the etiology of community-acquired pneumonia","volume":"37","author":"Arnold","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0010","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0011","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1164\/rccm.201501-0140OC","article-title":"Ten-year mortality after community-acquired pneumonia. a prospective cohort","volume":"192","author":"Eurich","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0012","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","article-title":"Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis","volume":"21","author":"Horita","year":"2016","journal-title":"Respirology"},{"key":"10.1016\/j.jgar.2022.05.009_bib0013","series-title":"The Cochrane Collaboration","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1","year":"2020"},{"key":"10.1016\/j.jgar.2022.05.009_bib0014","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.05.009_bib0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.jgar.2022.05.009_bib0016","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jgar.2022.05.009_bib0017","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0018","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2022.05.009_bib0019","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0020","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03261911","article-title":"High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study","volume":"32","author":"Lee","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jgar.2022.05.009_bib0021","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin","volume":"98","author":"L\u00e9ophonte","year":"2004","journal-title":"Respir Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0022","first-page":"321","article-title":"An open-label, randomized comparison of levofloxacin and amoxicillin\/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia","volume":"30","author":"Lin","year":"2007","journal-title":"Chang Gung Med J"},{"key":"10.1016\/j.jgar.2022.05.009_bib0023","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10096-005-1347-1","article-title":"Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors","volume":"24","author":"Portier","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.009_bib0024","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1086\/498149","article-title":"Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community-acquired pneumonia who received initial parenteral therapy","volume":"41","author":"Welte","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.009_bib0025","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11596-006-0411-0","article-title":"Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia","volume":"26","author":"Xu","year":"2006","journal-title":"J Huazhong Univ Sci Technolog Med Sci"},{"key":"10.1016\/j.jgar.2022.05.009_bib0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00151829-200403050-00006","article-title":"Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia","volume":"3","author":"Zervos","year":"2004","journal-title":"Treat Respir Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0027","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0028","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1179\/joc.2002.14.6.609","article-title":"Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy","volume":"14","author":"Romanelli","year":"2002","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2022.05.009_bib0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.03.00045202","article-title":"Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia","volume":"21","author":"Torres","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2022.05.009_bib0030","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"\u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.05.009_bib0031","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3389\/fphar.2019.00489","article-title":"Respiratory fluoroquinolones monotherapy vs. \u03b2-lactams with or without macrolides for hospitalized community-acquired pneumonia patients: a meta-analysis","volume":"10","author":"Liu","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jgar.2022.05.009_bib0032","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3906\/sag-1709-144","article-title":"Antibiotic treatment outcomes in community-acquired pneumonia","volume":"48","author":"\u00c7illi","year":"2018","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jgar.2022.05.009_bib0033","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2022.05.009_bib0034","first-page":"2967","article-title":"Etiology and antimicrobial resistance of community-acquired pneumonia in adult patients in China","volume":"125","author":"Tao","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.jgar.2022.05.009_bib0035","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004418.pub4","article-title":"Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults","author":"Eliakim-Raz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jgar.2022.05.009_bib0036","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/bmj.38334.591586.82","article-title":"Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis","volume":"330","author":"Mills","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2022.05.009_bib0037","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1001\/archinte.165.17.1992","article-title":"Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials","volume":"165","author":"Shefet","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jgar.2022.05.009_bib0038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1378\/chest.130.1.11","article-title":"Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia","volume":"130","author":"Waterer","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.jgar.2022.05.009_bib0039","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1186\/s12879-017-2495-5","article-title":"Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis","volume":"17","author":"Eljaaly","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.009_bib0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.idc.2012.11.004","article-title":"Does empirical therapy with a fluoroquinolone or the combination of a \u03b2-lactam plus a macrolide result in better outcomes for patients admitted to the general ward?","volume":"27","author":"Ruhe","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2022.05.009_bib0041","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","article-title":"Fluoroquinolones or macrolides alone versus combined with \u03b2-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis","volume":"46","author":"Raz-Pasteur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.05.009_bib0042","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.05.009_bib0043","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12845","article-title":"The dilemma of monotherapy or combination therapy in community-acquired pneumonia","volume":"47","author":"Vardakas","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jgar.2022.05.009_bib0044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s41479-020-00074-3","article-title":"Etiology of community-acquired pneumonia in adults: a systematic review","volume":"12","author":"Shoar","year":"2020","journal-title":"Pneumonia (Nathan)"},{"key":"10.1016\/j.jgar.2022.05.009_bib0045","first-page":"541","article-title":"[Distribution and antimicrobial resistance profile of common pathogens isolated from respiratory secretion in CHINET Antimicrobial Resistance Surveillance Program, 2005\u20132014]","volume":"16","author":"Yang","year":"2016","journal-title":"Chin J Infect Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:38Z","timestamp":1761991238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":45,"alternative-id":["S2213716522001138"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.05.009","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}